Health
These Dessert Teas Could Help You Drop Up to 9 Pounds in a Week
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Forgot your password?
Get back to the Sign In
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Health
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill is showing promising results, helping people drop 13% of their body weight in a three-month period.
The results from early clinical trials were presented by Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy — at the European Association for the Study of Diabetes (EASD) annual meeting in Madrid this week.
The drug, amycretin, works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.
‘SIX-PACK SURGERY’ GAINING POPULARITY AMONG MEN, SAY PLASTIC SURGEONS
“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, said in a statement sent to Fox News Digital.
“We are proud to present the phase 1 study results at EASD, showing that the mean change in percentage body weight was -13.1% with amycretin after 12 weeks of treatment.”
While Ozempic and Wegovy are administered via injection, amycretin is given as a 50-milligram oral pill.
The clinical trial included participants who were obese or overweight but did not have diabetes. Those who took amycretin for 12 weeks lost more weight than those on a placebo — and higher doses led to more weight loss, according to Novo Nordisk.
OZEMPIC PUSH FOR SENIORS? SOME DOCTORS SAY MORE PEOPLE AGE 65 AND OVER SHOULD BE ON IT
Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%.
Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight loss plateau,” continuing to shed pounds as long as they took it.
“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the study findings.
‘Dual effect’
Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, commented on the drug’s effectiveness.
OBESITY MAKES PEOPLE MORE LIKELY TO CATCH COVID, STUDY SUGGESTS: ‘INDISPUTABLE RELATIONSHIP’
“GLP-1-based treatments, like Ozempic, have already shown impressive weight loss results by helping patients feel fuller for longer and reducing appetite,” the doctor, who was not involved in the study, told Fox News Digital.
“Adding amylin, another hormone that plays a crucial role in regulating insulin and hunger signals, amplifies this effect.”
This “dual action” creates a more powerful tool to manage cravings and caloric intake, according to Ren-Fielding.
“It’s particularly interesting because it addresses weight management through multiple physiological pathways, making it more comprehensive and potentially more effective than conventional treatments that typically focus on a single mechanism,” she added.
Potential risks or side effects
The most commonly reported side effects of amycretin include gastrointestinal issues like nausea and vomiting, more so with higher doses, according to Novo Nordisk.
“These adverse effects are not unusual with GLP-1 receptor agonists, which are known to affect gastric motility,” Ren-Fielding noted.
“It addresses weight management through multiple physiological pathways.”
It’s important to monitor these side effects closely, she advised, as GI issues are common among patients with obesity.
“While the initial weight loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Ren-Fielding added.
‘Not a cure-all’
While GLP-1 based drugs — including this new experimental pill — may show promising results, Ren-Fielding emphasized that they’re “not a cure-all for obesity.”
“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she told Fox News Digital.
“Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions.”
Some patients may benefit from surgical interventions, the doctor said, along with lifestyle changes such as regular exercise, healthy eating and psychological support to address underlying behavioral factors.
“It’s important to recognize that obesity is not just about weight loss — it’s a lifelong condition that requires ongoing management, much like any other chronic disease,” she added.
Next steps
The results of the study are considered preliminary, as they have not yet been published in a peer-reviewed medical journal.
The researchers will continue to conduct research on amycretin in the coming months, according to Novo Nordisk.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“The safety and tolerability profiles and the magnitude of weight loss support further development of amycretin, and we are awaiting data from the ongoing phase 1 trial with subcutaneous amycretin, with expected read-out in 2025,” Lange said.
“If further research supports these initial findings, I can envision it becoming a viable option for those struggling with obesity.”
Ren-Fielding said there is “certainly potential” for the new drug to get FDA approval, especially considering the effectiveness of GLP-1-based drugs in recent years — but confirmed that much more testing is needed.
“The current clinical trials are promising, but we need larger, long-term studies to really assess the safety and overall benefits of the drug,” she told Fox News Digital.
For more Health articles, visit www.foxnews.com/health
“If further research supports these initial findings, I can envision it becoming a viable option for those struggling with obesity,” she went on.
“While I’m cautiously optimistic, there’s still a road ahead before we see widespread availability.”
Health
Kids who get less sleep face greater risk of future drug, alcohol use, study finds
A good night’s sleep has many proven benefits — potentially including a healthier future for kids.
New research from Penn State University analyzed how childhood sleep patterns could be linked to future substance use.
Researchers at the university found that adolescents who went to bed later and slept fewer hours during their childhood were more likely to have consumed alcohol or marijuana by the age of 15.
‘NAPUCCINO’ TREND: CAFFEINE BEFORE A NAP COULD BE KEY TO BETTER SLEEP
The study, published in the journal Annals of Epidemiology, looked at data of 1,514 children from 20 cities across the U.S., focusing on sleep duration and bedtime in different developmental stages.
Parents involved in the Future of Families and Child Wellbeing Study, from where the data was obtained, recorded their children’s bedtimes at ages 3, 5 and 9, as well as sleep duration at 5 and 9.
The results showed that teens were 45% more likely to try alcohol by age 15 if they had a later bedtime at age 9.
Bedtime at age 5, however, wasn’t associated with future alcohol use, nor was sleep duration at either age.
GOING TO BED AFTER THIS TIME COULD LEAD TO POORER MENTAL HEALTH, A STANFORD STUDY FINDS
Meanwhile, a later bedtime at age 5 was associated with a 26% increased likelihood of marijuana use by age 15.
Sleeping an hour less at age 9 led to a 19% increased chance of trying marijuana during adolescence.
15-year-olds also reported their bedtime, sleep duration and substance use, which revealed that those with a later bedtime had a 39% increased chance of drinking alcohol and a 34% chance of trying marijuana.
“By ensuring that children get adequate and high-quality sleep, we may protect long-term health and encourage positive health behaviors later in life.”
Adolescents who slept one hour less increased their odds of trying alcohol by 28%, but there was no association with marijuana.
SLEEPING LONGER ON WEEKENDS COULD LOWER HEART DISEASE RISK BY 20%, STUDY FINDS
In a statement sent to Fox News Digital, study co-author David A. Reichenberger, PhD — a researcher in the Department of Biobehavioral Health at Penn State — noted that the study only included participants who had complete data, “so that we could assess the effects across time within the same set of kids.”
“Overall, the implications of our results suggest that sleep may play a crucial role in whether children engage in substance use as teens,” he said.
“By ensuring that children get adequate and high-quality sleep, we may protect long-term health and encourage positive health behaviors later in life,” the researcher added.
Dr. Wendy Troxel, a senior behavioral and social scientist at RAND Corporation in Park City, Utah, shared with Fox News Digital how this study adds to growing evidence that sleep problems may lead to “risky health behaviors” later in life.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“These findings are consistent with my work conducted with my RAND colleagues, showing that poor sleep health in adolescence longitudinally predicts increases in alcohol and marijuana use in early adulthood,” she said.
“Importantly, this new data suggests that sleep problems even earlier in life can predict substance use during adolescence — a critical inflection point for the onset and exacerbation of drug and other alcohol use.”
Sleep problems may increase the likelihood of substance use due to affected decision-making, impulse control and emotion regulation skills, according to Troxel.
For more Health articles, visit foxnews.com/health
“Collectively, these findings point to the importance of addressing sleep problems using multi-level strategies, including family-based programs and public policies, such as later school start times, to promote sleep health in childhood and adolescence,” she said.
Health
How COVID affected teens' brains, plus new cancer drugs and Parkinson's risk
COVID BRAIN – New research found that pandemic restrictions had an “alarming” impact on teenagers’ brains. Get the details here. Continue reading…
MIDDAY PICK-ME-UP – A trending sleep hack is helping to boost energy levels – and it involves caffeine. Continue reading…
NEW HOPE – An existing breast cancer drug could help prolong survival for children with brain tumors, a new study finds. Doctors discuss its potential. Continue reading…
‘SIX-PACK’ SURGERY – More men are turning to a special surgical procedure to give them the look of chiseled abs. Plastic surgeons discuss the risks and benefits. Continue reading…
AVIAN ALERT – A U.S. state has reported the first human case of bird flu without any exposure to animals. Here’s what to know. Continue reading…
GUT-HEALTH CONNECTION – Damage to the digestive tract could significantly increase the risk of a common neurological disease. Continue reading…
VIRAL CONCERNS – The Wetland virus, a newly discovered rare disease in China, could cause brain damage or bleeding under the skin, researchers warn. Continue reading…
WELLNESS POINTS – Watching game shows could have a surprising health benefit. Discover the benefits of getting in the game. Continue reading…
ASK A DOCTOR – “Is it safe to drink tap water?” Experts give their guidance on the potential risks and share safety tips. Continue reading…
FOLLOW FOX NEWS ON SOCIAL MEDIA
YouTube
SIGN UP FOR OUR NEWSLETTERS
Fox News First
Fox News Opinion
Fox News Lifestyle
Fox News Health
Fox News Autos
Fox News Entertainment (FOX411)
DOWNLOAD OUR APPS
Fox News
Fox Business
Fox Weather
Fox Sports
Tubi
WATCH FOX NEWS ONLINE
Fox News Go
STREAM FOX NATION
Fox Nation
-
Business1 week ago
How Self-Driving Cars Get Help From Humans Hundreds of Miles Away
-
World1 week ago
Meloni says 'we are making history' as Italy’s FDI reviews progress
-
World1 week ago
Israeli forces using ‘war-like’ tactics in occupied West Bank: OCHA
-
Movie Reviews1 week ago
Queer: Daniel Craig shines in Luca Guadagnino’s steamy drama
-
World1 week ago
How Venezuela’s recent history can inform its present-day election crisis
-
News1 week ago
Georgia school shooting live updates: Casualties reported at Apalachee High School, suspect in custody
-
World1 week ago
Frontex chief: NGO rescue ships don't embolden Mediterranean migration
-
Politics1 week ago
Trump, Kamala aiming for the middle with varying degrees of success